Skip to main
ACON

Aclarion Inc (ACON) Stock Forecast & Price Target

Aclarion Inc (ACON) Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Aclarion Inc has demonstrated significant revenue growth, with a reported Q3 revenue increase of 31% year-over-year driven primarily by an 89% rise in Nociscan report volumes, indicating strong market demand for its healthcare technology solutions. The company's proactive approach to expand its sales and marketing efforts, including strategic partnerships with several medical institutions, positions it well for continued growth, particularly as it navigates favorable coverage decisions in the UK. Furthermore, the sustained momentum in scan volumes, exemplified by 132% year-over-year growth reported in Q2, reinforces a positive outlook on the company's financial trajectory as it seeks to optimize clinical treatments through its innovative SaaS platform, Nociscan.

Bears say

Aclarion Inc faces significant challenges which contribute to a negative outlook on its stock. The company is experiencing slower-than-expected traction with both surgeons and payers, combined with higher than anticipated marketing and administrative expenses, which is reflected in the downward adjustments of its FY25 EPS estimates. Furthermore, risks related to balance sheet liquidity, regulatory approvals, product commercialization, and the need for reimbursement add further pressure on the company's financial stability.

Aclarion Inc (ACON) has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Aclarion Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Aclarion Inc (ACON) Forecast

Analysts have given Aclarion Inc (ACON) a Strong Buy based on their latest research and market trends.

According to 1 analysts, Aclarion Inc (ACON) has a Strong Buy consensus rating as of Jan 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $23, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $23, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Aclarion Inc (ACON)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.